Sinovac Cash Problems? Bangladesh Phase 3 Clinical Trial at Risk

Oct 14, 2020 | Bangladesh, COVID-19, Investor Watch, News, Sinovac, Vaccine

Sinovac Cash Problems Bangladesh Phase 3 Clinical Trial at Risk

Bangladesh’s health ministry has rejected calls by China’s Sinovac Biotech to co-finance a Phase 3 COVID-19 vaccine-focused clinical trial in that country. Last month, Sinovac Biotech Ltd sent a letter to the health ministry declaring that unless funds were contributed, they would back out of the clinical trial in the world’s 8th most populous nation. But, apparently, this wasn’t the deal. Actually ,according to Bangladesh Health Minister Zahid Maleque, Sinovac had signed up to sponsor and fund the clinical trial. Why is Sinovac asking the nation of Bangladesh for money? Are they constrained on the cash front? They raised $15 million in a convertible note last year, which isn’t much given the world of COVID-19 vaccine development.

The Controversy

The Chinese biotech and vaccine developer, according to Reuters and Bangladeshi sources, committed to conduct the trial in the country if authorities in that nation approved the trial. The Health Minister was quoted, “A country’s job is done when it approves the clinical test of a vaccine. They never asked for co-funding when they sought approval for the trial. This is not a contract we have with the Chinese government. This is a private company and we cannot have a co-funding (arrangement) with a private company.”

Access Regardless

Health Minister Maleque reported the nation could access the vaccine if approved regardless. He said they would work with WHO and apparently also participated in a program involving early access to said vaccine in addition to a collaboration with India affording early access.

The Vaccine

As , Sinovac’s vaccine is known as Coronavac. The vaccine candidate is based on an “inactivated pathogen” developed by actually growing the whole virus in the lab and then killing the pathogen.

Financial & Other Problems?

Sinovac has had challenges with investors in the past, as reported by TrialSite. The company recently raised $15 million in a convertible note but frankly, this isn’t much money in the world of vaccine development. Are there concerns here?

Moreover, the company instituted a “poison pill” in 2019 to protect management from disgruntled shareholders. Did they have good reason to be upset?

Source:

1 Comment

  1. Muhammad Moinuddin

    What we observe, 74% of slum population having antibody developed without any covid-19 symptoms. Again 45% of Dhaka Metropolitan City are having covid-19 antibody in their blood. We think Bangladeshi don’t need mass vaccination. Useless to spend money on a private company. Moreover, we do early diagnosis and treatment for COVID-19 to prevent the disease treating with Ivermectin + Doxycycline + Zink + Vir D3 + Famotidine.
    Mass prophylaxis may be done with Ivermectin combination declaring a day for it throughout the country, then again after one week another dose of Ivermectin. Controversial vaccination without trials must be avoided, because it is a curable disease with less than 1% fatality in Bangladesh. Out of 170,000,000 population only 5,800 patients have fatal outcome which is less than heart attack death rate and RTA death rate.

    Reply

Submit a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. .

Pin It on Pinterest